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Abstract
HLA-B*27 exerts protective effects in hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections. While the
immunological and virological features of HLA-B*27-mediated protection are not fully understood, there is growing
evidence that the presentation of specific immunodominant HLA-B*27-restricted CD8+ T-cell epitopes contributes to this
phenomenon in both infections. Indeed, protection can be linked to single immunodominant CD8+ T-cell epitopes and
functional constraints on escape mutations within these epitopes. To better define the immunological mechanisms
underlying HLA-B*27-mediated protection in HCV infection, we analyzed the functional avidity, functional profile, antiviral
efficacy and naı¨ve precursor frequency of CD8+ T cells targeting the immunodominant HLA-B*27-restricted HCV-specific
epitope as well as its antigen processing and presentation. For comparison, HLA-A*02-restricted HCV-specific epitopes were
analyzed. The HLA-B*27-restricted CD8+ T-cell epitope was not superior to epitopes restricted by HLA-A*02 when
considering the functional avidity, functional profile, antiviral efficacy or naı¨ve precursor frequency. However, the peptide
region containing the HLA-B*27-restricted epitope was degraded extremely fast by both the constitutive proteasome and
the immunoproteasome. This efficient proteasomal processing that could be blocked by proteasome inhibitors was highly
dependent on the hydrophobic regions flanking the epitope and led to rapid and abundant presentation of the epitope on
the cell surface of antigen presenting cells. Our data suggest that rapid antigen processing may be a key immunological
feature of this protective and immunodominant HLA-B*27-restricted HCV-specific epitope.
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Introduction
The human leukocyte antigen (HLA) B*27 is associated with a
high rate of spontaneous viral clearance in hepatitis C virus (HCV)
infection [1,2] and with slow disease progression in human
immunodeficiency virus (HIV) infection [3,4]. In both infections,
the protective role has been linked to single immunodominant
CD8+ T-cell epitopes [5–9]. Virological and immunological
mechanisms contribute to the HLA-B*27-mediated protection.
For example, extensive virological studies have demonstrated that
viral escape from CD8+ T-cell responses that target the protective
immunodominant HLA-B*27-restricted epitopes in both HIV and
HCV infection is difficult to achieve and requires the accumula-
tion of several mutations. In HIV infection, three mutations within
and outside the immunodominant HLA-B*27-restricted epitope
(KK10) are required for viral escape: the first mutation has an
immunmodulatory effect, a second mutation compensates for viral
fitness costs, and a third mutation abrogates HLA binding [10–
13]. In HCV infection, viral escape mutations are not tolerated at
the HLA-B*27 binding anchors of the epitope due to a major
impact on viral replicative fitness. Mutations at T-cell-receptor
contact residues can occur in this otherwise highly conserved
region; however, several of these mutations are required for full
escape due to broad T-cell cross-recognition of viral variants [14].
Thus, in both infections, related but distinct mechanisms constrain
virological escape and contribute to protection.
In contrast, the immunological mechanisms that contribute to
HLA-B*27-mediated protection are less well understood. It is
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possible that certain characteristics of HLA-B*27-restricted CD8+
T cells may contribute to the protective effect. Indeed, functional
avidity, defined as the sensitivity of CD8+ T cells to antigenic
stimulation, has been proposed to correlate with the outcome of
viral infection [15–19]. For example, one study found that the
functional avidity of HLA-B*27-restricted HIV-specific CD8+ T-
cell responses directed against the protective immunodominant
KK10 epitope was higher in comparison to responses directed
against epitopes restricted by other HLA-alleles [15]. Others
reported that the functional avidity of KK10-specific CD8+ T-cell
responses was comparable to that of responses targeting subdom-
inant HLA-B*27-restricted epitopes derived from HIV [18]. It has
also been suggested that immunodominant HLA-B*27-restricted
HIV-specific CD8+ T-cell responses display more potent antiviral
efficacy compared to responses targeting subdominant HLA-B*27-
restricted epitopes [18].
Another factor that has been suggested to contribute to the
superior control of HIV replication is the polyfunctionality of the
immunodominant KK10-specific CD8+ T cells [15]. Polyfunc-
tionality is characterized by the simultaneous production of
multiple effector-molecules such as CD107a, IFN-c, IL-2, MIP-
1b and TNF-a.
However, since HLA-B*27-mediated protection is also closely
linked to the immunodominance of HLA-B*27-restricted virus-
specific CD8+ T-cell responses, it is tempting to speculate that
factors determining immunodominance may help explain this
protective effect. Immunodominance is expected to be determined
early after infection when naı¨ve antigen-specific CD8+ T cells
encounter their antigen and the first responses start to emerge.
Factors that contribute to CD8+ T-cell immunodominance
include antigen processing and presentation, abundance of
peptide-major histocompatibility complex class I (pMHCI) mol-
ecules on antigen-presenting cells (APCs) and the number of naı¨ve
T cells that express complementary T-cell receptors [20]. Studies
primarily performed in mouse models have shown that the
immunodominance hierarchy and the magnitude of T-cell
responses are shaped by the number of antigen-specific naı¨ve
CD8+ T cells [21–23]. Consistent with these findings, we have
shown that the immunodominance hierarchy of HLA-A*02-
restricted HCV-specific CD8+ T-cell responses observed in
chronically HCV infected subjects is related to the frequency of
naı¨ve CD8+ precursors [24]. However, there is also growing
evidence that immunodominance is largely influenced by differ-
ences in antigen processing [25–28]. One study has demonstrated
that antigen processing strongly influences CD8+ T-cell response
hierarchies in HIV infection as the amount of epitope produced
correlated with CD8+ T-cell response magnitude and frequency
[29]. Moreover, proteasomal cleavage of HIV Gag-derived
polypeptides by the immunoproteasome efficiently generated
precursors of the HIV-specific HLA-B*27-restricted protective
immunodominant KK10 epitope as well as minute amounts of the
optimal epitope itself [29,30]. The ‘optimal’ epitope is defined as
the epitope form that results in the greatest in vitro stimulation of
epitope-specific CD8+ T-cell responses.
In this comprehensive study, we set out to elucidate the
immunological factors that mediate the protection afforded by
HLA-B*27 in HCV infection. Compared to HLA-A*02-restricted
HCV-specific CD8+ T-cell responses, we found that the protective
effect of the immunodominant HLA-B*27-restricted HCV-specific
epitope is not clearly linked to differences in the intrinsic properties
of cognate CD8+ T-cell populations, but rather to more rapid and
efficient antigen processing and presentation. These results suggest
that both immunodominance and protection in this case are
associated with the kinetics and efficacy of epitope generation.
Results
Functional avidity of protective immunodominant HLA-
B*27-restricted HCV-specific CD8+ T-cell populations
In a first set of experiments, we assessed the functional avidity of
HCV-specific CD8+ T-cell populations from chronically HCV
infected subjects. For comparative purposes, CD8+ T-cell
populations specific for three frequently recognized HLA-A*02-
restricted epitopes were evaluated in addition to those specific for
the immunodominant HLA-B*27-restricted NS5B2841 epitope
(Table 1). All four epitopes bind comparably and with high
affinity to their restricting HLA class I molecule [31]. In HLA-
A*02+ tested subjects only one or a maximum of two epitope-
specific CD8+ T cell responses were detectable and thus analyzed.
It is important to note, that in all functional assays performed in
this study, short term expanded HCV-specific CD8+ T-cell lines
(14 days) were used. Circulating HCV-specific CD8+ T cells in
chronically infected subjects are only present at a very low
frequency (usually ,0.1% of total CD8+ T cells); this does not
allow the performance of functional analyses.
Table 1. HLA-A*02 and -B*27 restricted epitopes.
Allele
Amino Acid
Position
Peptide
Length Sequence IC50 (nM)*
HLA-A*02 NS31073 9 CINGVCWTV 66.5
HLA-A*02 NS31406 10 KLVALGINAV 52.8
HLA-A*02 NS5B2594 9 ALYDVVSKL 11.8
HLA-B*27 NS5B2841 9 ARMILMTHF 28.4
*IC50 was determined by using the immune epitope database (IEDB, http://
www.immuneepitope.org/).
doi:10.1371/journal.ppat.1003042.t001
Author Summary
HLA-B*27 has a protective effect in hepatitis C virus (HCV)
infection which could be linked to a single highly
immunodominant HLA-B*27-restricted CD8+ T-cell epi-
tope. However, the immunological mechanisms determin-
ing this protective effect are poorly understood. In this
study, we analyzed multiple immunological determinants
that may contribute to the protective role of the HLA-
B*27-restricted HCV-specific epitope and its strong im-
munodominance and compared them with HLA-A*02-
restricted HCV-specific epitopes. Our data indicate that the
protective effect of the HLA-B*27-restricted epitope
cannot be explained by a higher sensitivity for antigen
stimulation, a higher proportion of effector-functions or a
superior ability to inhibit viral replication of epitope-
specific CD8+ T cells. We also did not find a higher naı¨ve
precursor frequency of HLA-B*27-restricted CD8+ T cells.
However, we could show that the peptide region
containing the HLA-B*27-restricted epitope is character-
ized by rapid antigen processing that was mostly due to
the hydrophobic flanking regions of the epitope. This
results in a faster presentation of the epitope at the cell
surface of antigen presenting cells. Our results suggest
that rapid antigen processing may be a key mechanism
contributing to the protective effect of the immunodomi-
nant HLA-B*27-restricted epitope. These findings have
clear implications for the design of antiviral vaccines.
Rapid Processing and Protection in HCV Infection
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After two weeks of peptide-specific expansion, cytotoxic T
lymphocyte (CTL) lines were stimulated with HLA-B*27+ or HLA-
A*02+ subject-derived EBV-immortalized B-cell lines pulsed with
serial peptide concentrations (Figure 1A); the response EC50 was
quantified as the exogenous peptide concentration required to yield
half-maximal frequencies of cells producing intracellular IFN-c, as
shown in Figure 1B. Importantly, HLA-B*27-restricted CD8+ T
cells displayed a significantly lower mean functional avidity (indicated
by a significantly higher mean EC50 value) compared to HLA-A*02-
restricted CD8+ T cells from the same subject group (Figure 1C).
Since the presence of chronic infection may affect the properties of
virus-specific CD8+ T-cell populations, we also analyzed the
functional avidity of CD8+ T cells obtained from subjects with
resolved HCV infection. Interestingly, HLA-B*27-restricted CD8+ T
cells from subjects with resolved HCV infection displayed a higher
mean functional avidity compared to cells obtained from chronically
infected HLA-B*27+ subjects although this difference was not
statistically significant (Figure 1C). However, this did not exceed
the mean functional avidity observed for HLA-A*02-restricted
epitopes targeted in chronic or resolved infection. Thus, superior
functional avidity is not a characteristic of HLA-B*27-restricted CD8+
T cells specific for the protective immunodominant NS5B2841 epitope
when compared to HLA-A*02-restricted CD8+ T-cell populations.
Functional profile of protective immunodominant HLA-
B*27-restricted HCV-specific CD8+ T-cell populations
In order to compare the functional profile of HLA-B*27- and
HLA-A*02-restricted CD8+ T cells from chronically HCV-infected
subjects we performed intracellular multi-cytokine staining. Upon
peptide-specific stimulation, HLA-B*27- and HLA-A*02-restricted
CTL lines produced the same array of cytokines with even similar
quantities (Figure 2A). Particularly, CD107a was mobilized and
IFN-c, MIP-1b and TNF-a were produced by CD8+ T cells
restricted by both HLA-alleles. However, production of IL-2 by all
virus-specific CD8+ T cells was limited (Figure 2A) and neither
HLA-B*27- nor HLA-A*02-restricted CD8+ T cells produced IL-4,
IL-10, IL-17A or IL-22 (data not shown). The direct number of
functions (polyfunctional profile) of individual CD8+ T cells is shown
in Figure 2B and 2C. Although CD8+ T cells restricted by both
alleles produced similar amounts of the same cytokines, individual
HLA-B*27-restricted CD8+ T cells produced more cytokines
Figure 1. Functional avidity of HCV-specific CD8+ T cells. (A) Representative flow cytometry plots showing intracellular IFN-c staining of a CTL
line exposed to target cells pulsed with a range of peptide concentrations. PBMCs from a subject chronically infected with HCV were stimulated for
two weeks with the HLA-A*02-restricted NS31073 epitope. Prior to intracellular IFN-c staining, the CTL line was cocultured for 5 hours with HLA-A*02+
EBV-immortalized B-cell lines (B-LCLs) pulsed with serially diluted concentrations of the cognate peptide. The background value from the negative
control (B-LCLs without peptide loading) was subtracted from all measured response frequencies (IFN-c+ CD8+/total CD8+). (B) Representative data
from intracellular IFN-c staining of a CTL line specific for the HLA-A*02-restricted NS31073 epitope (filled circles) and a CTL line specific for the HLA-
B*27-restricted NS5B2841 epitope (open circles) across a range of peptide concentrations. The background value from the negative control (B-LCLs
without peptide loading) was subtracted from all measured response frequencies (IFN-c+ CD8+/total CD8+), which were then normalized to the
maximum response by defining the smallest value as 0% and the largest value as 100%. (C) The functional avidity of CTL lines, derived from
chronically HCV infected subjects, specific for HLA-A*02-restricted epitopes (n = 7, filled circles) and the immunodominant HLA-B*27-restricted
epitope NS5B2841 (n = 6, open circles), as well as of CTL lines derived from subjects with resolved infection specific for HLA-A*02-restricted epitopes
(n = 3, filled squares) and the immunodominant HLA-B*27-restricted epitope NS5B2841 (n = 4, open squares). Functional avidity was determined as the
concentration of peptide required to achieve half-maximal IFN-c induction (EC50). P-values were calculated using the Mann-Whitney U-test.
Horizontal bars represent mean values.
doi:10.1371/journal.ppat.1003042.g001
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simultaneously compared to HLA-A*02-restricted CD8+ T cells.
Importantly, they showed a higher proportion of CD107a+, IFN-c+
and MIP-1b+ cells. These results suggest that HLA-B*27- and HLA-
A*02-restricted CD8+ T cells derived from chronically infected
subjects have similar functional qualities with comparable quantities
even though their polyfunctional profile at a cell based level may
slightly differ.
Antiviral efficacy of protective immunodominant HLA-
B*27-restricted HCV-specific CD8+ T-cell populations
Next, we analyzed whether HLA-B*27-restricted NS5B2841
epitope-specific CD8+ T cells exert superior antiviral efficacy
compared to CD8+ T cells of other specificities. In HIV infection,
it has been suggested that a protective immunodominant HLA-
B*27-restricted CD8+ T-cell response is characterized by superior
antiviral activity [18]. To address this possibility, we used human
hepatoma HuH7 cells harboring a JFH1-based selectable sub-
genomic luciferase replicon to measure the inhibition of HCV
replication by CD8+ T cells. These replicon cells were transduced
with lentiviral vectors expressing HLA-A*02 or HLA-B*27 with a
selectable marker conferring blasticidin resistance controlled by
the constitutive cellular EF1a promoter, as described previously
[32]. The resulting cell lines showed strong and homogeneous
expression of HLA-A*02 or HLA-B*27, respectively, by flow
cytometric analysis (data not shown). The inhibitory effect on
HCV replication was measured by determining luciferase activity,
which is fully dependent on HCV RNA replication and correlates
precisely with intracellular levels of viral RNA antigens [32]. Since
the subgenomic replicon is based on the genotype 2a isolate JFH1
and its sequence is not cross-recognized by the respective CD8+ T
cells specific for genotype 1a peptides, pulsing with respective
peptide is required (genotype 1a sequence, see Table 1). HuH7
cells expressing HLA-A*02 were pulsed with increasing concen-
trations of specific HLA-A*02-restricted peptides and HuH7 cells
Figure 2. Functional profile of HCV-specific CD8+ T cells. (A) Cytokine production and CD107a mobilization of CTL lines, derived from
chronically HCV infected subjects specific for HLA-A*02-restricted epitopes (n = 4, black bars) and the immunodominant HLA-B*27-restricted epitope
NS5B2841 (n = 4, white bars). Prior to intracellular multi-cytokine staining CTL lines were stimulated for 5 hours with specific peptides. The background
value from the negative control (without peptide) was subtracted from all measured response frequencies (cytokine+ CD8+/total CD8+). Data are
presented as mean 6 SD. (B) Pie charts showing the mean multifunctionality of HLA-A*02-restricted (n = 4) and HLA-B*27-restricted (n = 4) HCV-
specific CD8+ T-cell lines (one to five functions: CD107a, IFN-c, IL-2, MIP-1b and TNF-a). Responding cells are grouped by the number of functions
indicated by the numbers in the pie charts and matched to the color code in figure 2C. (C) Detailed functional profile of HLA-A*02-restricted (n = 4,
black bars) and HLA- B*27-restricted (n = 4, white bars) HCV-specific CD8+ T-cell lines. Bars represent frequency of CD8+ T cells displaying the
indicated combination of functions within the total population of responding CD8+ T cells. P-values were calculated using the Mann-Whitney U-test.
Data are presented as mean 6 SD.
doi:10.1371/journal.ppat.1003042.g002
Rapid Processing and Protection in HCV Infection
PLOS Pathogens | www.plospathogens.org 4 November 2012 | Volume 8 | Issue 11 | e1003042
expressing HLA-B*27 were pulsed with increasing concentrations
of the dominant HLA-B*27 peptide. The target cells were then
cocultured with respective peptide-specific CTL lines at an
effector-to-target (E:T) ratio of 1:1. Importantly, as shown in
Figure 3, virus-specific CD8+ T cells blocked HCV replication in
a peptide dose-dependent manner that correlated precisely with
the amount of IFN-c secreted by the virus-specific T cells. Of note,
HLA-B*27-restricted CD8+ T cells specific for the NS5B2841
epitope derived from chronically infected subjects did not mediate
superior antiviral efficacy. HLA-A*02-restricted CD8+ T cells
started to inhibit HCV replication at a lower peptide concentra-
tion (1028) compared to HLA-B*27-restricted CD8+ T cells
(Figure 3A and B). We additionally analyzed the antiviral
efficacy of CD8+ T cells derived from subjects with resolved HCV
infection (Figure 3C and D). HLA-B*27-restricted CD8+ T cells
from subjects with resolved HCV infection displayed a higher
antiviral efficacy compared to cells obtained from chronically
infected HLA-B*27+ subjects. However, they were not much
superior to HLA-A*02-restricted CD8+ T cells obtained from
subjects with chronic or resolved infection. These findings show
that the antiviral efficacy is correlated with the functional avidity of
CD8+ T cells and suggest that the protective effect of the
immunodominant HLA-B*27-restricted epitope is not explained
by the antiviral efficacy of epitope-specific CD8+ T cells.
Naı¨ve precursor frequency of protective
immunodominant HLA-B*27-restricted HCV-specific
CD8+ T cells
Next, we asked whether the strong immunodominance of the
NS5B2841 epitope might be dictated by a high frequency of naı¨ve
CD8+ T-cell precursors. To address this issue, we analyzed naı¨ve
precursor frequencies of CD8+ T cells specific for the NS5B2841
epitope and compared it to the well described immunodominant
HLA-A*02-restricted NS31406 epitope. Of note, we recently
showed that the immunodominance of this latter epitope is linked
to a relatively high frequency of epitope-specific naı¨ve precursors
[24]. By using a previously described combination of tetramer
staining, magnetic-bead enrichment and multiparametric flow
cytometry [33], we were able to detect naı¨ve HCV-specific CD8+
T cells in all four HLA-B*27 and all eight HLA-A*02 healthy
donors analyzed (Figure 4). Although the cells were not
detectable before the enrichment step, they could be clearly
identified after enrichment, as shown for one representative
subject in Figure 4A. The cells displayed a naı¨ve phenotype
characterized by high expression of CD45RA, CD27 and CCR7,
and low expression of CD11a (data not shown). Of note, the naı¨ve
precursor frequency of HLA-B*27-restricted CD8+ T cells specific
for NS5B2841 was not significantly higher compared to the
frequency of the immunodominant HLA-A*02-restricted naı¨ve
Figure 3. Antiviral efficacy of HCV-specific CD8+ T cells. Antiviral efficacy (white bars) and functional avidity (filled circles) of CTL lines, derived
from subjects with a chronic HCV infection specific for (A) HLA-A*02-restricted epitopes (n = 3) and (B) the immunodominant HLA-B*27-restricted
epitope NS5B2841 (n = 3) as well as of CTL lines derived from subjects with resolved infection specific for (C) HLA-A*02-restricted epitopes (n = 3) and
(D) the immunodominant HLA-B*27-restricted epitope NS5B2841 (n = 3). HuH7A2HCV and HuH7B27HCV cell lines were pulsed with a range of cognate
peptide concentrations and cocultured for 24 hours with CTL lines at an E:T ratio of 1:1. Inhibition of viral replication was measured by luciferase
activity. As a reference, intracellular IFN-c staining at corresponding peptide concentrations is indicated. Measured RLUs and IFN-c responses were
normalized to maximum viral replication or maximum IFN-c response, respectively, by defining the smallest value as 0% and the largest value as
100%. Data are presented as mean 6 SD.
doi:10.1371/journal.ppat.1003042.g003
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precursors (Figure 4B, data of HLA-A*02-restricted naı¨ve
precursors were previously published [24]). These data suggest
that the strong immunodominance of the HLA-B*27-restricted
NS5B2841 epitope is not due to an intrinsically high naı¨ve
precursor frequency, at least across HLA restriction elements.
Proteasomal processing of the protective
immunodominant HLA-B*27-restricted NS5B2841 epitope
Recently, it has been shown that antigen processing influences
HIV-specific CD8+ T-cell response hierarchies [29]. In case of an
HLA-B*27-restricted HIV Gag-derived epitope, immunodomi-
nance correlated with abundant proteasomal production of a
range of short and long, naturally processed peptide forms
containing the optimal epitope [29]. We therefore analyzed
whether proteasomal cleavage of the dominant NS5B2841 epitope
has an influence on the immunodominant response to this epitope.
Specifically, we performed a proteasomal digest of a 25-amino
acid peptide containing the HLA-B*27-restricted dominant
NS5B2841 epitope, as well as two peptides containing the HLA-
A*02-restricted epitopes NS31073 and NS5B2594 (Figure 5A),
using constitutive proteasomes and immunoproteasomes in
parallel over a time course of six hours. Subsequently, the
resulting fragments were analyzed by mass spectrometry. Our
initial proteasomal digestion experiments resulted in production of
the optimal HLA-A*02-restricted NS31073 and NS5B2594 (A2-
NS31073 and A2-NS5B2594) epitopes, but surprisingly failed to
yield any of the HLA-B*27-restricted NS5B2841 (B27-NS5B2841)
epitope or even B27-NS5B2841 epitope-containing fragments
(Figure 5B). Indeed, the 25-mer B27-NS5B2841 polypeptide was
completely degraded and only peptides of four to nine amino acids
in length could be detected (Figure 5C). We therefore performed
additional digestion experiments with this polypeptide substrate at
a four-fold dilution of both proteasomal forms. By using this more
sensitive approach, we were able to detect small amounts of the
optimal B27-NS5B2841 epitope after four to six hours of
immunoproteasomal digestion. Importantly, we also observed six
additional longer peptides containing the B27-NS5B2841 epitope,
each of which was present at concentrations exceeding that of the
optimal B27-NS5B2841 epitope by up to 300-fold (Figure 5D; the
optimal B27-NS5B2841 epitope as well as all B27-NS5B2841
epitope-containing fragments are highlighted in black). Because
some of these fragments ended at the C-terminal end of the
analyzed 25-mer peptide, and production thus was a maximum
estimate, we performed additional proteasomal digestions of an
overlapping, but more C-terminal 25-mer peptide encompassing
B27-NS5B2841. These proteasomal digestions demonstrated cleav-
age C-terminal of the first analyzed fragment (Figure S1).
Although epitope production was less than indicated by the
maximum estimates of our first experiment, the overall production
of the B27-NS5B2841 epitope-containing fragments still comprised
between 8–32% of all digestion products (data not shown). To
investigate whether the rapid proteasomal processing was due to
the B27-NS5B2841 sequence itself, or to the very hydrophobic
regions flanking this epitope, we generated an artificial chimeric
25-mer peptide containing the B27-NS5B2841 epitope imbedded in
the regions flanking the A2-NS5B2594 epitope (termed B27-in-A2).
We found that this B27-in-A2 peptide degraded in a manner more
similar to the original A2-in-A2 25-mer peptide than the original
B27-in-B27 peptide (Figure 6). Indeed, the chimeric B27-in-A2
peptide degraded slightly more slowly than the A2-in-A2 peptide
following immunoproteasomal digestion and although we doubled
the amount of proteasome used in this experiment, we could not
increase the rate of degradation to that of the original B27-in-B27
peptide. Consequently, the hydrophobicity of the B27-NS5B2841
epitope flanking region is critical to the rapid processing of this
epitope. Our data furthermore suggests that the combination of
epitope and flanking region affect the overall peptide degradation
rate.
Figure 4. Precursor frequency of HCV-specific CD8+ T cells. (A) Representative flow cytometry plots of PBMCs from a healthy donor displaying
staining with the NS5B2841/HLA-B*27 tetramer before and after magnetic-bead enrichment. Percentage of tetramer+ CD8+ T cells is indicated. (B)
Precursor frequencies of CD8+ T cells specific for NS31406 (HLA-A*02 tetramer, filled circles) and NS5B2841 (HLA-B*27 tetramer, open circles) detected
in healthy donors after tetramer staining, magnetic-bead enrichment and multiparametric flow cytometric analysis. The enriched tetramer+ CD8+ T-
cell populations were stained for CD45RA, CD27, CCR7 and CD11a. The number of phenotypically naı¨ve (CD45RAhi, CD27hi, CCR7hi, CD11alow)
tetramer+ CD8+ T cells relative to the number of total CD8+ T cells is indicated. Horizontal bars represent mean values.
doi:10.1371/journal.ppat.1003042.g004
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In order to analyze whether during degradation of the chimeric
B27-in-A2 peptide the optimal epitope is generated, we compared the
amount of optimal 9-mer B27-NS5B2841 epitope generated following
digestion of the artificial chimeric B27-in-A2 peptide with that made
following processing of the natural B27-in-B27 peptide (Figure S2).
Our data show that more of the optimal B27-NS5B2841 epitope was
released following both constitutive and immunoproteasomal diges-
tion when the epitope was in the A2-NS5B2594 flanking context,
although the epitope was produced more slowly. It is important to
note, that we compared only the amounts of optimal 9-mer epitope.
Longer versions of the B27-NS52841 epitope are not produced
following processing of the artificial chimeric B27-in-A2 construct
while these are made in great amounts when the 25-mer peptide with
the natural B27-in-B27 amino acid sequence is processed.
As it has been shown previously that HLA-B*27 is able to bind
and present peptides that are N- or C-terminally extended
fragments of an optimal epitope [29,34], we next examined the
cross-recognition of the seven B27-NS5B2841 epitope-containing
peptide forms using non-specifically expanded CD8+ selected T
cells derived from two chronically HCV infected HLA-B*27+
subjects by intracellular cytokine staining for IFN-c. Importantly,
these CD8+ T cells responded to almost all naturally processed
B27-NS5B2841 epitope-containing peptides (Figure 7A and B). In
one subject, some of the long peptide variants induced even
slightly stronger IFN-c production compared to the optimal B27-
NS5B2841 epitope (data not shown). In these experiments, we used
non-specifically expanded CD8+ T cells rather than peptide-
stimulated T-cell lines because they best represent the range of
CD8+ T-cell populations found in subjects in vivo. To confirm
specificity, we also analyzed the capability of the NS5B2841
epitope-containing peptide forms to stimulate the expansion of
epitope-specific CD8+ T cells derived from chronically infected
Figure 5. Proteasomal digestion of HCV-specific epitope-containing regions. (A) Peptides of 24 (A2-NS31073) and 25 (A2-NS5B2594 and B27-
NS5B2841) amino acids in length spanning the regions containing the respective epitopes were used for incubation with constitutive proteasomes
and immunoproteasomes. Epitope sequences are underlined. (B) Production of epitope-containing and non-epitope-containing cleavage products of
the 24-mer (A2-NS31073) and two 25-mer (A2-NS5B2594 and B27-NS5B2841) peptides incubated with constitutive proteasomes and immunoprotea-
somes for 1 to 6 hours using standard conditions. The sum of all fragment intensities was set at 100%. Data are representative of triplicate
experiments. (C) The relative production of all cleavage products of the B27-NS5B2841 peptide by constitutive proteasomes and immunoproteasomes
for 1 to 6 hours using standard conditions. All fragments were between 4 and 9 amino acids long. Data are representative of triplicate experiments.
(D) The relative production of all cleavage products of the B27-NS5B2841 peptide by constitutive proteasomes and immunoproteasomes for 1 to
6 hours using a 46dilution of both of the proteasomal forms. The abundance of B27-NS5B2841-containing fragments ending in a C-terminal
2857D
represents a maximum as this corresponds to the end of the 25-mer peptide substrate. All fragments containing the NS5B2841 epitope are highlighted
using black symbols. The NS5B2841 epitope sequence is underlined. Data are representative of triplicate experiments.
doi:10.1371/journal.ppat.1003042.g005
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HLA-B*27+ subjects; all tested peptide forms were able to
stimulate epitope-specific CD8+ T-cell expansions in culture
(Figure 7C).
Rapid and efficient presentation of the protective
immunodominant HLA-B*27-restricted HCV-specific
epitope
The rapid proteasomal cleavage of the HLA-B*27-restricted
NS5B2841 epitope prompted us to investigate whether this leads to
faster epitope presentation on the cell surface of APCs. Since it is
hypothesized that the timing of antigen abundance at the cell
surface of antigen presenting cells during initial priming of naive
HCV-specific CD8+ T may influence the immunodominace
hierarchy of responding CD8+ T cells [25,35] and since it is
assumed that APCs rather than hepatocytes initially prime naı¨ve
HCV-specific CD8+ T cells (reviewed by [36–38]), we decided to
use subject-derived APCs for our assays. Due to the lack of
approved models of expanded subject-derived DCs we decided to
use EBV-immortalized B-cell lines that best fit to this model of
antigen processing and presentation. HLA-B*27+ and HLA-
A*02+ EBV-immortalized B-cell lines were infected with vaccinia
virus constructs encoding HCV proteins containing the relevant
peptides. Importantly, the sequence of the vaccinia virus construct
is identical to the sequence of the polypeptides used for our
proteasomal digestion experiments (genotype 1a). Subsequently,
after infection the cells were cultured for different incubation times
(0–24 h) to allow endogenous antigen processing, then added to
peptide-specific CTL lines restricted by HLA-B*27 or HLA-A*02,
respectively (Figure 8A). Induction of IFN-c production as a
read-out for antigen presentation was measured by intracellular
cytokine staining after five hours of cocultivation. As shown for
representative subjects in Figure 8B and C and for all subjects
tested in Figure 8D, antigen-specific CD8+ T cell IFN-c
production became detectable within two to four hours of vaccinia
virus infection, suggesting that endogenously processed epitopes
had already reached the surface of the APC in this time period.
Importantly, the induction of IFN-c in HLA-B*27-restricted
CD8+ T cells was higher at two and four hours after infection
compared to HLA-A*02-restricted CD8+ T cells, even despite the
lower avidity of the HLA-B*27-restricted CD8+ T-cell responses
(Figure 8D). When corrected for functional avidity in individual
subjects (Figure S3), a significantly higher level of the HLA-B*27-
restricted NS5B2841 peptide was presented at the cell surface
compared to HLA-A*02-restricted epitopes at these time points
(Figure 8E). Finally, we analyzed the influence of proteasome
inhibitors on the endogenous antigen processing and their effect
on the timing of the induction of antigen-specific IFN-c
production of HLA-B*27 and HLA-A*02-restricted CTL lines.
By using the proteasome inhibitor epoxomicin we were able to
delay the induction of epitope-specific IFN-c production and
considerably decrease the number of responding CD8+ T cells
(Figure 8F). We also performed control experiments with the
Figure 6. Epitope precursor degradation rates of natural HLA-A*02- and HLA-B*27-restricted epitopes as well as of an artificial
chimeric epitope. The percentage of undigested 25-mer precursor peptide left following 1, 2, 4, and 6 hours of constitutive and
immunoproteasomal digestion, respectively. The amino acid sequences of the examined 25-mer peptides are shown with imbedded optimal
epitopes underlined and the amount of purified proteasomal solution is indicated. B27-in-A2 signifies the B27-NS5B2841 epitope surrounded by the
A2-NS5B2594 flanking regions, while A2-in-A2 and B27-in-B27 show these epitopes in their natural sequence contexts. The grey line indicates 50%
degradation of the precursor peptide. Data are representative of triplicate experiments.
doi:10.1371/journal.ppat.1003042.g006
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proteasome inhibitor lactacystin and saw 30–70% reductions in
the number of responding CD8+ T cells (data not shown). These
data support the assumption that proteasomal digestion more
likely than alternative cytosolic proteases, such as the tricorn, is
responsible for the production of HCV-specific epitopes. In sum,
these results demonstrate that, following endogenous processing
via the proteasome, the HLA-B*27-restricted NS5B2841 epitope
more rapidly reaches a higher peptide concentration on the cell
surface compared to HLA-A*02-restricted epitopes, and that this
translates to kinetically enhanced induction of antigen-specific
IFN-c production.
Discussion
In this study, we set out to determine the immunological
mechanisms that contribute to the protective effect associated with
the immunodominant HLA-B*27-restricted NS5B2841 epitope in
HCV infection. Importantly, we found that protection cannot be
clearly linked to CD8+ T-cell responses characteristics, such as
functional avidity or antiviral efficacy. Indeed, it was the first
finding of our study that in chronic infection protective
immunodominant HLA-B*27-restricted CD8+ T-cell responses
had lower functional avidity than HLA-A*02-restricted CD8+ T-
Figure 7. Cross-recognition patterns of all B27-NS5B2841-containing fragments derived from immunoproteasomal digestion. (A)
Representative flow cytometry plots showing intracellular IFN-c staining with CD8+ T cells from one subject across a range of peptide concentrations.
PBMCs from HLA-B*27+ subjects chronically infected with HCV were enriched for CD8+ T cells and expanded non-specifically for 14 days. The
background value from the negative control (without peptide loading) was subtracted from all measured response frequencies (IFN-c+ CD8+/total
CD8+). Tested peptide sequences are indicated. (B) Representative cross-recognition patterns of all naturally processed B27-NS5B2841-containing
fragments by enriched and non-specifically expanded CD8+ T cells (see Figure 7A). Responses were measured by intracellular IFN-c staining against
serial dilutions of all 7 B27-NS5B2841-containing peptide forms. The background value from the negative control (without peptide loading) was
subtracted from all measured response frequencies (IFN-c+ CD8+/total CD8+). Symbol code for peptide sequences is indicated in Figure 7C. (C)
Representative cross-recognition patterns of the NS5B2841- peptide by PBMCs specifically expanded by all naturally processed B27-NS5B2841-
containing fragments. PBMCs from subjects chronically infected with HCV were stimulated for two weeks with all 7 B27-NS5B2841-containing peptide
forms separately (see indicated symbol code). Responses were measured by intracellular IFN-c staining against serial dilutions of the NS5B2841-
peptide. The background value from the negative control (without peptide loading) was subtracted from all measured response frequencies (IFN-c+
CD8+/total CD8+).
doi:10.1371/journal.ppat.1003042.g007
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cell responses. These results contrast somewhat with previous
studies performed in HIV infection, which have observed that
CD8+ T-cell responses restricted by HLA-B alleles have a higher
functional avidity than those restricted by HLA-A alleles. Most
notably, HLA-B*27-restricted CD8+ T-cell responses specific for
the immunodominant HIV Gag-derived epitope KK10, which is
associated with slow disease progression, displayed the highest
functional avidity when tested using the optimal epitope [15,16].
In contrast, however, CD8+ T-cell responses towards longer
natural processed peptide forms of this epitope have a much lower
functional avidity than those against the optimal epitope [29].
Thus, in the infected host CD8+ T-cell cross-recognition of
optimal and natural peptide forms may result in biased in vitro
estimations of functional avidity and magnitude of epitope-specific
CD8+ T-cell responses when only using the optimal epitope. In
HCV infection, Yerly et al. observed higher levels of functional
avidity for CD8+ T-cell responses in subjects who cleared the virus
compared to CD8+ T-cell responses derived from subjects with
Figure 8. Processing and presentation of HCV-specific CD8+ T-cell epitopes. (A) APCs were infected with vaccinia virus constructs carrying
the relevant part of the HCV polyprotein (vHCV 827). After a defined time period (0, 2, 4, 8, 12, 16, 20 and 24 hours) these APCs were added to HCV-
specific CTL lines and antigen-specific IFN-c production was assessed by flow cytometry. (B) Representative flow cytometry plots of a CTL line
stimulated with infected APCs. Prior to intracellular IFN-c staining, the epitope-specific CTL line was stimulated for 5 hours with APCs previously
infected with vHCV 827 and pre-incubated for 2, 4, 8 and 12 hours respectively. The background value from the negative control (T7 RNA polymerase
(vTF7)) was subtracted from all measured response frequencies (IFN-c+ CD8+/total CD8+). (C) Representative time course showing intracellular IFN-c
staining of an HLA-A*02-restricted CTL line (filled circles) and an HLA-B*27-restricted (open circles) CTL line stimulated with infected APCs pre-
incubated for 0 to 24 hours. The background value from the negative control (vTF7) was subtracted from all measured response frequencies (IFN-c+
CD8+/total CD8+), which were then normalized to the maximum response by defining the smallest value as 0% and the largest value as 100%. The
complete kinetic (0 to 24 hours) was performed for all subjects, and the normalized responses were used to generate the data shown in Figure 8D
and E. (D) Responses of CTL lines against APCs infected with vHCV 827 and pre-incubated for 2, 4 and 8 hours. Normalized IFN-c responses of CTL
lines specific for HLA-A*02-restricted epitopes (n = 9, filled circles) and for the immunodominant HLA-B*27-restricted NS5B2841 epitope (n = 7, open
circles) are shown. Responses were normalized to the maximum response, as described for Figure 8C. Horizontal bars represent mean values. (E)
Calculated peptide concentration present at the surface of infected APCs after 2, 4 and 8 hours of incubation with vHCV 827. The concentration of
presented peptide restricted by HLA-A*02 (n = 9, filled circles; Table 1) and HLA-B*27 (NS5B2841; n = 7, open circles) was calculated by correcting for
the individual functional avidity of the respective peptide-specific CTL line. For details of the calculations, see Figure S3. P-values were calculated
using the Mann-Whitney U-test. Horizontal bars represent mean values. (F) Representative time course showing intracellular IFN-c staining of an HLA-
B*27-restricted CTL line stimulated with infected APCs incubated for 0 to 8 hours and pre-incubated with (triangles) or without (squares) the
proteasome inhibitor epoxomicin. The background value from the negative control (vTF7) was subtracted from all measured response frequencies
(IFN-c+ CD8+/total CD8+). Data are representative of experiments performed with two different HLA-B*27-restricted CTL lines and one HLA-A*02-
restricted CTL line.
doi:10.1371/journal.ppat.1003042.g008
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chronic HCV infection [19]. Although we also found a higher level
of functional avidity for HLA-B*27-restricted CD8+ T-cell
responses derived from subjects with resolved versus chronic
HCV infection, this functional avidity was still lower compared to
HLA-A*02-restricted CD8+ T-cell responses. Collectively, our
results suggest that the overall protective effect of HLA-B*27 in
HCV infection cannot be linked to superior functional avidity even
when we used the optimal HCV-epitope in our experiments. This
conclusion is in keeping with a recent study by Harari et al., who
did not find a correlation between functional avidity and
protective CD8+ T-cell responses specific for several viruses [17].
In addition to functional avidity, we studied other aspects of the
CD8+ T-cell response to the protective immunodominant HLA-
B*27-restricted NS5B2841 epitope. Notably, we found that the
antigen-specific naı¨ve CD8+ T-cell precursor frequency for this
epitope was not substantially different compared to an immuno-
dominant HLA-A*02-restricted epitope. This is particularly
interesting in the light of previous studies suggesting that the
number of naı¨ve precursors plays a key role in the generation of
immunodominance hierarchies during viral infections in mouse
models and humans [21,23,24,39]. However, detailed comparison
with subdominant HCV-derived HLA-B*27-restricted epitopes
would be required to interpret this observation fully. Furthermore,
we found no evidence that CD8+ T-cell responses to the protective
immunodominant HLA-B*27-restricted NS5B2841 epitope medi-
ated enhanced antiviral efficacy. This observation is somewhat
perplexing when searching solely for an immunological explana-
tion for the protective effect of the HLA-B*27-restricted NS5B2841
epitope, but gains credence in the context of combined virological
considerations. In addition, it should be noted that this parameter
was assessed in the context of peptide-pulsed cell lines due to
system constraints. In the context of naturally presented epitopes,
it remains feasible that rapid and efficient antigen processing could
translate into enhanced antiviral efficacy in vivo. We finally
analyzed the functional profile of HCV-specific CD8+ T cells
and found that HLA-B*27- and HLA-A*02-restricted CD8+ T
cells have the same combination of functions with similar amounts
of produced effector-molecules. However, it is important to note
that HLA-B*27-restricted CD8+ T cells have a higher capacity to
simultaneously produce multiple effector-molecules compared to
HLA-A*02-restricted CD8+ T cells. This is in line with studies
performed with HIV-specific CD8+ T cells which have shown that
CD8+ T cells specific for the immunodominant HIV KK10-
epitope display a superior polyfunctional profile compared to
CD8+ T cells restricted by other HLA-alleles [15] and that
polyfunctionality is generally connected with a superior control of
HIV infection [40]. However, differences in polyfunctionality were
much lower in our study compared to these studies performed in
HIV infection.
The most important finding of our study is that the protective
effect of the immunodominant HLA-B*27-restricted NS5B2841
epitope can be linked to extraordinarily rapid processing by both
proteasomal forms and fast presentation of the epitope at the cell
surface. These important data were obtained by different but
complementary, experimental approaches. First, by using bio-
chemical assays with purified constitutive proteasomes and
immunoproteasomes, we demonstrated that the region containing
the HLA-B*27-restricted NS5B284 epitope is rapidly processed
resulting in fast generation of epitope precursors. We furthermore
show that this rapid processing mainly is due to the very
hydrophobic regions flanking the NS5B284 epitope, which is in
line with the finding of Lucciari-Hartz et al. who demonstrated that
processing of hydrophobic protein regions of HIV was more
efficient than that of hydrophilic regions [41]. In this context, it is
important to note that proteasomal digestion generated the
optimal HLA-B*27-restricted NS5B2841 epitope only in small
amounts and mainly produced longer precursors of this epitope.
However, these naturally processed longer NS5B2841-containing
peptide fragments could be cross-recognized by CD8+ T cells
derived from chronically HCV infected subjects. These results
indicate that HLA-B*27 may be able to present these extended
peptide forms [34] and that optimal epitopes are not necessarily
the epitope peptide forms produced most frequently in the infected
host [29].
Interestingly, the important role of antigen processing and
presentation of protective immunodominant viral epitopes has also
been demonstrated recently for the protective immunodominant
HLA-B*27-restricted HIV Gag-derived KK10 epitope. Specifi-
cally, the optimal KK10 epitope was generated only in minimal
amounts while epitope precursors of this epitope were produced
efficiently by proteasomal cleavage [29]. Therefore, the predom-
inance of proteasomal production of long peptides comprising the
NS5B2841 epitope, rather than the optimal NS5B2841 epitope itself,
is similar to the situation observed previously for the KK10
epitope. Likewise, the patterns of CD8+ T-cell cross-recognition
and response magnitudes specific for the optimal NS5B2841
epitope and the longer NS5B2841-containing peptides in our
experiments are similar to those found in subjects with chronic
HIV infection who respond to the KK10 epitope [29]. However,
the HLA-B*27-restricted NS5B2841 epitope-containing region is
processed significantly faster than the HIV Gag-derived KK10
epitope.
Importantly, by using functional T-cell assays, we could show
that the rapid processing of the protective immunodominant
HLA-B*27-restricted NS5B2841 epitope resulted in early presen-
tation at the surface of APCs. Collectively, these results support the
hypothesis that early antigen processing kinetics, rather than
absolute epitope quantities, help to elicit the protective immuno-
dominant HLA-B*27-restricted NS5B2841 response. This has not
previously been observed in humans, but is in agreement with
analyses of CD8+ T-cell response hierarchies in normal and
immunoproteasome-deficient mice infected with Listeria monocyto-
genes. Indeed, without immunoproteasomal processing, the pre-
sentation of an otherwise immunodominant epitope was delayed
and failed to evoke a CD8+ T-cell response [25]. Thus, the
magnitude and kinetics of antigen-specific CD8+ T-cell responses
appear to be determined during the first 24 hours after infection.
Furthermore, T-cell response hierarchies were defined before the
peak of the inflammatory response and prior to substantial
bacterial replication [42]. In addition, competition for the same
APC between T cells of different specificities has been shown to
occur within the first 5 hours of immunization and to affect the
number of T cells responding to a specific antigen in mice [43].
These results may in part be due to the highly regulated capture,
processing and presentation of antigens by dendritic cells, which
may only have a limited window-of-opportunity to present antigen
and engage in long, stable interactions with naı¨ve T cells [35].
Thus, epitopes that are processed and presented faster than others
may have a relatively greater chance of evoking early and
abundant T-cell responses in infected subjects similar to what has
been suggested for infected or immunized mice [25,35]. This
notion is supported by a study showing that the magnitude of
HIV-specific CD8+ T-cell responses restricted by HLA-A alleles
was dramatically lower in the presence of the protective alleles
HLA-B*27 and HLA-B*57, but not in the presence of other HLA-
B alleles [44]. In concert with these studies, our results support the
biological relevance of rapid processing and presentation in early
viral infection, which may in turn lead to the efficient induction of
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immunodominant and possibly protective CD8+ T-cell responses.
Importantly, the analysis of the proteasomal degradation of an
artificial chimeric peptide containing of the optimal B27-NS5B2841
epitope surrounded by the A2-NS5B2594 flanking regions showed
that the optimal epitope can be produced in higher amounts in this
context compared to that of the natural B27-NS5B2841 epitope-
containing peptide. These results suggest that for the design of an
HCV vaccine construct the timing but also the amount of epitope
processed by the proteasome can be manipulated through
modifications of the epitope itself as well as of the epitope flanking
regions. As discussed above epitope amount may not be as
important as the timing of epitope presentation for the priming of
virus-specific CD8+ T cells in acute infection; however it may play
a more important role for the priming of CD8+ T cells using a
vaccine.
Taken together, our findings suggest that immunological factors
such as rapid antigen processing and presentation contribute to
immunodominance hierarchies and combine with virological
factors such as functional constraints on viral escape to generate
protective CD8+ T-cell responses in human viral infections such as
HIV and HCV. Our results also suggest that HCV immunogens
could be modified and optimized in vitro to increase the rate of
proteasomal processing and thus the likelihood of evoking
abundant, or perhaps even immunodominant, CD8+ T-cell
responses towards any epitope. This possibility has clear implica-
tions for the design of an HCV vaccine.
Materials and Methods
Ethics statement
Written informed consent was obtained in all cases and the
study was conducted in agreement with the 1975 Declaration of
Helsinki, federal guidelines and local ethics committee regulations.
The ethics committee of the Albert-Ludwigs-Universita¨t, Freiburg
approved the study.
Study subjects
Twelve subjects with chronic HCV infection (six HLA-A*02+
and six HLA-B*27+) who presented to the University Hospital of
Freiburg were included in the study. In addition, six subjects with
resolved HCV infection (two HLA-A*02+, one double-positive
HLA-A*02+/HLA-B*27+ and three HLA-B*27+) and eleven
healthy individuals were included. Peripheral blood mononuclear
cells (PBMCs) were isolated from EDTA anticoagulated blood
samples using lymphocyte separation medium density gradients
(PAA Laboratories GmbH).
Tetramer enrichment and precursor frequency
determination
Procedural details are similar to those described by Alanio et al.
[33]. In brief, PBMCs (1–26108) were incubated for 15 minutes at
4uC with FcR blocking reagent (Miltenyi Biotec) and stained for
30 minutes with pMHCI tetramer conjugated to allophycocyanin
(APC), with the pMHCI component at 20 nM final concentration.
A small aliquot of the labeled cells was removed for staining (pre-
enriched fraction) and the remaining cells were incubated for
20 minutes at 4uC with anti-APC microbeads (Miltenyi Biotec).
Again, a small aliquot was removed for counting the pre-enriched
fraction and the remaining cells were passed over a magnetic-
activated cell separation column (Miltenyi Biotec). After removal
of the column from the magnet, the bound cell population
(enriched fraction) as well as the flow-through (depleted fraction)
were collected and stained. The frequency of the naı¨ve epitope-
specific T-cell population was determined using a calculation
similar to that of Alanio et al. [33], specifically the absolute
number of phenotypically naı¨ve (CD45RAhi, CD27hi, CCR7hi,
CD11alow) tetramer+ CD8+ T cells/the absolute number of CD8+
T cells was calculated.
Antibody staining and multiparametric flow cytometry
Cell populations (pre-enriched, enriched and depleted fractions)
were labeled with a combination of anti-CD45RA-phycoerythrin
(PE), anti-CD27-APC-eFlour780 (eBioscience), anti-CD8-AmC-
yan, anti-CCR7-PE-Cy7, anti-CD3-Pacific-Blue and anti-CD11a-
fluorescein isothiocyanate (FITC) monoclonal antibodies (mAbs;
BD Biosciences). Viaprobe (7-AAD; BD Biosciences) was used for
the exclusion of dead cells. The cells were stained in PBS
supplemented with 5% fetal calf serum (Pan-Biotech) for
20 minutes and washed twice before and after addition of the
staining reagents. All samples were acquired using a FACS Canto
II flow cytometer (BD Biosciences) and analyzed with FlowJo
software (TreeStar Inc.).
Peptides and tetramers for cellular analyses
Peptides corresponding to immunodominant HCV-epitopes
restricted by HLA-A*02 (CINGVCWTV, KLVALGINAV and
ALYDVVSKL) and HLA-B*27 (ARMILMTHF), as well as long
peptide forms of ARMILMTHF, were synthesized with a free
amino and carboxy terminus by standard Fmoc chemistry
(Genaxxon Bioscience). All peptides were dissolved and diluted
according to previously reported protocols [45]. Tetrameric
pMHCI complexes were generated as described previously [46].
CD8+ selection and polyclonal expansion of PBMCs
Procedural details were performed as described previously [9].
In brief, CD8+ T cells were enriched from PBMCs using magnetic
beads coupled to anti-CD8 mAbs (Dynabeads, Dynal) and a
particle magnetic concentrator. The enriched CD8+ fractions
were cultured in 2 mL complete medium (RPMI 1640 (Gibco)
containing 10% fetal calf serum, 1% streptomycin/penicillin
(Invitrogen) and 1.5% HEPES buffer, 1 mol/L (Biochrom))
supplemented with 100 U/mL recombinant human interleukin-2
(rIL-2; Hoffmann-La Roche), 0.04 mg/mL anti-human CD3 mAb
(Immunotech) and irradiated autologous PBMCs. Twice per week,
1 mL medium supplemented with 200 U/mL IL-2 was ex-
changed. On day 14, the expanded CD8+ cells were used for
intracellular IFN-c staining.
Stimulation of PBMCs with synthetic peptides
Experiments were performed as described previously [9]. In
brief, PBMCs (46106) were resuspended in 1 mL complete
medium and stimulated with peptide at 10 mg/mL final concen-
tration in the presence of 0.5 mg/mL anti-CD28 mAb (BD
PharMingen). On days 3 and 10, 1 mL complete medium
supplemented with rIL-2 at 20 U/mL final concentration was
added. On day 7, the cultures were restimulated with the
corresponding peptide (10 mg/mL) and 16106 irradiated autolo-
gous PBMCs. On day 14, the cells were used for intracellular IFN-
c staining.
Recombinant expression vectors and kinetic assays for
the endogenous processing of peptides
The recombinant vaccinia virus construct vHCV 827, which
encodes all relevant HCV peptides according to the sequence of
genotype 1a, together with a vaccinia virus encoding the T7 RNA
polymerase (vTF7) (both generously provided by Charles Rice,
Rockefeller University, New York [47]), were used to induce
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transient expression of endogenously processed HCV peptides in
HLA-matched EBV-immortalized B-cell lines (B-LCLs). B-LCLs
were infected at a multiplicity of infection (MOI) of 50 for 1 hour
with vHCV 827 and vTF7, or with vTF7 alone as a negative
control, and washed. The infected B-LCLs were incubated for
defined time periods (0, 2, 4, 8, 12, 16, 20 and 24 hours) at 37uC
and added as stimulators to peptide-specific CTL lines prior to
intracellular IFN-c staining. For proteasome inhibition assays B-
LCLs were incubated for 1.5 hours with 2 nM epoxomicin
(Calbiochem) or 50 nM lactacystin (Calbiochem) prior to vaccinia
virus infection.
Intracellular IFN-c and multicytokine staining
Procedures were performed as described previously [45]. In
brief, peptide-specific CTL lines were stimulated with HLA-
matched B-LCLs pulsed with increasing concentrations of
corresponding peptide (1029–1024 M), or with HLA-matched B-
LCLs infected with vHCV 827, at an E:T ratio of 1:1. Cells were
then incubated for 5 hours in the presence of 50 U/mL human
rIL-2 and 1 mL/mL brefeldin A (BD PharMingen). After
incubation, cells were blocked with immunoglobulin G1 (IgG1)
and stained with anti-CD8-PE mAb (BD Biosciences). Following
fixation/permeabilization with Cytofix/Cytoperm (BD PharMin-
gen), cells were stained with anti-IFN-c-FITC mAb (BD Biosci-
ences), then fixed in 100 mL CellFIX (BD PharMingen) prior to
flow cytometric analysis.
For multicytokine staining cells were incubated for 5 hours in
the presence of 1025 M specific peptide, 50 U/mL human rIL-2,
0.325 mL/mL monensin (BD PharMingen) and 0.5 mL/mL
brefeldin A (BD PharMingen). After incubation, cells were blocked
with IgG1 and stained with anti-CD8-APC H7 (BD PharMingen)
mAb. Following fixation/permeabilization with Cytofix/Cyto-
perm, cells were stained with anti-CD107a-PE (BD PharMingen),
anti-IFN-c-eFlour450 (eBioscience), anti-IL-2-PerCP-Cy5.5 (Bio-
Legend), anti-MIP-1b-FITC (R&D Systems), and anti-TNF-a-PE-
Cy7 (BD PharMingen) mAbs, or anti-IFN-c-eFlour450, anti-IL-4-
PE (BD PharMingen) and anti-IL-10-APC (BD PharMingen)
mAbs or anti-IFN-c-eFlour450, anti-IL-17A-PE (eBioscience) and
anit-IL-22-APC (R&D Systems) mAbs then fixed in 100 mL
CellFIX prior to flow cytometric analysis.
Cell culture
HuH7-Lunet cells were transduced with the JFH1-based
selectable subgenomic luciferase replicon and a selectable lentiviral
vector expressing the complementary DNA of HLA-A*02
(HuH7A2HCV) or HLA-B*27 (HuH7B27HCV) [32]. Generation
of the HLA-B*27 expressing vector [48], the HLA-A*02
expressing vector [32] and the JFH1-based selectable subgenomic
luciferase replicon [32] were performed as described previously.
Cells were grown in Dulbecco’s modified Eagle medium high
glucose (4.5 g/L) with stable glutamine (PAA Laboratories GmbH)
supplemented with 10% fetal calf serum, 1% penicillin/strepto-
mycin and nonessential amino acids (Biochrom). For continuous
passage, the culture medium was supplemented with 1 mg/mL
G418 (PAA Laboratories GmbH) and 10 mg/mL blasticidin S
hydrochloride (Carl Roth GmbH & Co).
Viral inhibition assay
HuH7A2HCV and HuH7B27HCV replicon cells were pulsed for
1 hour with increasing concentrations of corresponding peptide
(1029–1024 M) and washed intensively. Pulsed replicon cells were
then cocultured with peptide-specific CTL lines at an E:T ratio of
1:1. After 24 hours, the inhibition of viral replication was
measured by luciferase activity.
Luciferase assay
Luciferase activity was detected using the Steady-Glo Luciferase
Assay System (Promega) and measured with Luminoskan
Ascent (Thermo Fischer) and expressed as relative luciferase unit
(RLU).
Purification of 20S proteasomes
Constitutive and immuno-20S proteasomes were purified from
LCL721.174 and LCL721 human EBV-transformed B cell lines as
described previously [49]. LCL721.174 originate from LCL721
but carry only one copy of chromosome 6, which contains a
deletion of the TAP1 and 2, LMP2 and LMP7 genes in the MHC
class II region.
Peptide synthesis, HPLC and purification for processing
studies
Peptides were synthesized on a MK-IV peptide synthesizer,
HPLC purified and verified by LC-MS on an HPLC Shimadzu
QP8000-system (Schafer-N). Additional purification to .98%
purity was performed prior to proteasomal peptide digestion
experiments using a JupiterProteo (25062.1 mm) column (Phe-
momenex) on a SMART HPLC system (Amersham) as described
previously [29].
In vitro proteasomal peptide digests and mass
spectrometry analyses
Proteasomal digestions were performed as described previously
[29]. In brief, 2 nmol of each peptide was incubated for 2, 4 and
6 hours with 2 mg (or 4 mg in the degradation experiment) of
either purified immunoproteasome or constitutive proteasome in
digestion buffer (20 mM HEPES-NaOH pH 7.6, 2 mM MgAc2,
0.5 mM DTT), and samples were diluted 1:5 before injection into
the mass spectrometer. All peptide digests were performed on the
same day. Although a range of peptide fragment lengths was
obtained following digestion of the two HLA-A*02-restricted
epitope-containing 25-mers (NS3: 1065AT1099, A02-
CINGVCWTV; and, NS5B: 2587VY2611, A02-ALYDVVSKL),
similar to results reported previously for HIV 25-mer peptides
[29], the HLA-B*27 epitope-containing peptide (NS5B:
2833ID2857, B27-ARMILMTHF) was completely degraded; only
4–9 mer peptides were detected, and none contained the epitope.
Consequently, the experiments were repeated with a 1:4 dilution
of the purified immunoproteasome or constitutive proteasome
stock solution, and these samples were diluted 1:2 before injection
into the mass spectrometer. Mass spectrometry analyses of peptide
digests were performed as described previously [29]. In brief,
peptide digests were analyzed by nanoscale liquid chromatography
using a Waters NanoAcquity UPLC system, with a Waters
NanoEase BEH-C18, 75 mm615 cm reversed phase column.
Mass spectrometry analysis of peptide fragments was performed
using a Waters Q-Tof Premier in positive Vmode equipped with a
nano-ESI. For fragment identification and relative quantification
of the peptide fragments, the instrument was run in MSE-mode.
Each sample was analyzed in triplicate. Data processing, fragment
identification and quantification of LC-MSE data was performed
using ProteinLynx Global Server (PLGS) version 2.2 or Mas-
sLynx4.1 software. Quantification of the remaining substrate was
performed using LC-MSE data and ProteinLynx Global Server
(PLGS) version 2.2, and peptide identifications were assigned by
database searches containing the full-length peptide sequences.
The mass error tolerance values were mostly under 5 ppm.
Precursor degradation rates were quantified manually via extract-
ed ion chromatograms.
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Statistical analysis
Statistical analysis was performed using GraphPad Prism 5
software (GraphPad Prism Software, Inc.). P-values were calcu-
lated using the Mann-Whitney U-test.
Supporting Information
Figure S1 Proteasomal digestion occurs at 2857D and C-
terminal to 2857D. (A) The relative production of B27-
NS5B2841-containing digestion products with specific C-terminal
endings (F, A, R, D, Q and L) by constitutive proteasomes and
immunoproteasomes for 1 to 6 hours using standard conditions.
For these experiments a C-terminally extended B27-NS5B2841-
containing 25-mer peptide was used (amino acid sequence as
indicated, the NS5B2841 epitope sequence is underlined). Data are
representative of triplicate experiments. (B) Sequences of all B27-
NS5B2841-containing digestion products ending at F, A, R, D, Q
and L respectively.
(TIF)
Figure S2 Production of optimal epitopes. Production of
optimal B27-NS5B2841 and A2-NS5B2594 epitopes in percentage
of all peptide fragments produced following constitutive and
immunoproteasomal digestion, respectively, of the artificial
chimeric B27-in-A2 peptide and the two natural A2-in-A2 and
B27-in-B27 amino acid sequences.
(TIF)
Figure S3 Calculation of peptide levels present at the
surface of infected antigen-presenting cells. Representa-
tive calculation of peptide levels present at the surface of infected
APCs after 8 hours of incubation. The normalized frequency of
the IFN-c response that is achieved after a defined time of
incubation can be transferred to the peptide titration curve and
used to identify the peptide level that is required to achieve the
same response frequency.
(TIF)
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